ConductScience.org, home

Paper39240337

Therapeutic drug monitoring in tuberculosis.

Sarkar M and 1 other. Eur J Clin Pharmacol, 2024. Cited by 11 papers, by iCite.

Cite this record

ConductScience Library. Therapeutic drug monitoring in tuberculosis. Papers, record 39240337. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39240337

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Therapeutic drug monitoring in tuberculosis.
PubMed
Journal
Eur J Clin Pharmacol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
11
iCite
Relative citation ratio, by iCite
2.22, provisional
iCite
Revised in PubMed
2026-11-01
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sarkar MM
2Sarkar JJ

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug MonitoringMajor topic
Antitubercular AgentsMajor topic
TuberculosisMajor topic
Humans
Drug Interactions
Tuberculosis, Multidrug-Resistant
HIV Infections

Source PubMed

Download CSV of topics

References166

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125809764Therapeutic drug monitoring: how to improve drug dosage and patient safety in tuberculosis treatment.Int J Infect Dis2015https://conductscience.org/library/papers/25809764PubMed
231729908Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.Am J Respir Crit Care Med2019https://conductscience.org/library/papers/31729908PubMed
330496457Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis.Clin Infect Dis2018https://conductscience.org/library/papers/30496457PubMed
43778104[Permanent malabsorption of rifampicin in a diabetic with celiac disease].Arch Fr Pediatr1986https://conductscience.org/library/papers/3778104PubMed
520498324Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.Antimicrob Agents Chemother2010https://conductscience.org/library/papers/20498324PubMed
632747933Clofazimine pharmacokinetics in patients with TB: dosing implications.J Antimicrob Chemother2020https://conductscience.org/library/papers/32747933PubMed
726828056End TB with precision treatment!Eur Respir J2016https://conductscience.org/library/papers/26828056PubMed
821834763Dried blood spots: a new tool for tuberculosis treatment optimization.Curr Pharm Des2011https://conductscience.org/library/papers/21834763PubMed
938708036Role of therapeutic drug monitoring in the treatment of multi-drug resistant tuberculosis.J Clin Tuberc Other Mycobact Dis2024https://conductscience.org/library/papers/38708036PubMed
1016028152Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.Clin Infect Dis2005https://conductscience.org/library/papers/16028152PubMed
1129735562Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29735562PubMed
1229701775Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.J Antimicrob Chemother2018https://conductscience.org/library/papers/29701775PubMed
1333684562Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis.Int J Infect Dis2021https://conductscience.org/library/papers/33684562PubMed
1425678771Profile of delamanid for the treatment of multidrug-resistant tuberculosis.Drug Des Devel Ther2015https://conductscience.org/library/papers/25678771PubMed
158371737Malabsorption of antimycobacterial medications.N Engl J Med1993https://conductscience.org/library/papers/8371737PubMed
1625676682Safety and tolerability profile of second-line anti-tuberculosis medications.Drug Saf2015https://conductscience.org/library/papers/25676682PubMed
1724349775Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA.Tuberc Res Treat2013https://conductscience.org/library/papers/24349775PubMed
1828584143Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis.Antimicrob Agents Chemother2017https://conductscience.org/library/papers/28584143PubMed
1921310881Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience.Eur Respir J2011https://conductscience.org/library/papers/21310881PubMed
2025861340Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in virginia, 2009-2014.Tuberc Respir Dis (Seoul)2015https://conductscience.org/library/papers/25861340PubMed

See all 166 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.

PMIDTitleJournalYearIn PapersSource
42010496Towards precision dosing of contezolid: moderate hepatic impairment increases plasma concentration of contezolid in anti-tuberculosis treatment.BMC Infect Dis2026https://conductscience.org/library/papers/42010496PubMed
41605541Host- and pathogen-related determinants of pulmonary versus extrapulmonary tuberculosis.Eur Respir Rev2026https://conductscience.org/library/papers/41605541PubMed
41566098Therapeutic Drug Monitoring for Improving Tuberculosis Treatment Outcomes: A Scoping Review of Clinical Studies.Clin Pharmacokinet2026https://conductscience.org/library/papers/41566098PubMed
41254567Construction and clinical application of an innovative pharmacist-led service model for therapeutic drug monitoring in tuberculosis treatment: a pragmatic randomized controlled trial.BMC Pulm Med2025https://conductscience.org/library/papers/41254567PubMed
41204126Global burden of HIV and drug-resistant tuberculosis co-infection and its attributable risk factors, 1990 to 2021, with projections to 2031.BMC Infect Dis2025https://conductscience.org/library/papers/41204126PubMed
40698037Extensive, Multifocal Pott Disease in a United States-Born Veteran Without Human Immunodeficiency Virus.Open Forum Infect Dis2025https://conductscience.org/library/papers/40698037PubMed
39841361Tuberculosis vaccines and therapeutic drug: challenges and future directions.Mol Biomed2025https://conductscience.org/library/papers/39841361PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39240337

GET https://conductscience.org/api/papers/v1/39240337/references?page=2